Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
GLOBETECH PUBLISHING
JIB

Metabolic Pathway Discovered Has Implications for Diabetes, Obesity, Cancer Therapy

By BiotechDaily International staff writers
Posted on 18 Oct 2012
A newly discovered hedgehog-signaling pathway has been found to be a primary regulator of cellular energy metabolism and to include insulin-independent glucose uptake.

Scientists from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg (Freiburg, Germany) and the Medical University of Vienna (Vienna, Austria) together with an international research team have jointly resolved this pathway, which also involves the known activation of Smo upon binding of Sonig Hedgehog (Shh) to its membrane receptor Patched (Ptch). Smo controls the previously known hedgehog pathway through transcription factors, whereas it controls the newly discovered, must faster, alternative hedgehog pathway through calcium-dependent activation of an AMP-kinase. This rewires metabolism so that the cell can now rapidly absorb large quantities of glucose, rebalancing anabolism and catabolism. Further, rather than promoting efficient energy metabolism through mitochondria, this pathway promotes the much less efficient lactic acid fermentation, the process cancer cells use to acquire their energy anaerobically, as in the Warburg effect.

The US Food and Drug Administration approved the first hedgehog inhibitor, Vismodegib, for treatment of cancer this year. There are presently at least six further agents being tested in clinical studies. Surprisingly, the first patient cohorts receiving Vismodegib have shown serious side effects, such as weight loss and muscle cramps, to the extent that more than half of the participants discontinued use. “Activation of the AMP-kinase and increased catabolism could explain the exaggerated weight loss of the participants in the clinical studies. More importantly though, the influx of calcium into muscle cells leads to instant contraction, and must be triggering the cramps,” explained Prof. Andrew Pospisilik from the Max Planck Institute in Freiburg. Hedgehog inhibitors do not have to lead to these side effects. “We targeted the Smo protein with various substances and found out that there are inhibitors that do not evoke an increase in calcium or glucose values, and, critically, these same inhibitors fail to cause muscle cells to contract in culture," said Prof. Pospisilik.

The scientists also found that cultured fat cells dramatically increase the glucose quantity they can absorb – without relying on insulin. This finding was confirmed by glucose-tolerance tests on mice treated with the classic hedgehog inhibitor cyclopamine, which showed correspondingly lower blood glucose than untreated mice. “Agents that only activate the Smo-calcium/AMP-kinase hedgehog signaling pathway are therefore candidates as medications for treating excess body weight, as well as type-1 and type-2 diabetes. Similar to the broad hedgehog inhibitors, they possess the potential to induce muscle cramps. Thanks to our findings, we now know that a new agent must first be tested on muscle cells before it is used on humans,” said Prof. Harald Esterbauer of the Medical University of Vienna.

The study was published October 12, 2012, in the journal Cell.


Related Links:
Max Planck Institute of Immunobiology and Epigenetics in Freiburg
Medical University of Vienna


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Scanning electron micrograph of cultured human neuron from induced pluripotent stem cell (Photo courtesy of the University of California, San Diego).

Induced Stem Cells Show Genetic Abnormalities Not Found in Embryonic Stem Cells

All stem cells are not created equal: genomic evaluation revealed that the genome of stem cells generated from adult cells (induced pluripotent stem cells or iPS cells) differed considerably from that... Read more

Drug Discovery

view channel
Image: A mouse mammary gland missing the tumor-suppressor p53 shows expression of ARF (green), now known for a backup role in protecting cells from becoming cancerous. If both p53 and ARF are mutated, the tumors that form are aggressive and may benefit from treatment with anti-inflammatory drugs called JAK inhibitors, currently prescribed for rheumatoid arthritis (Photo courtesy of Raleigh Kladney).

Anti-Inflammatory Drugs May Treat Some Aggressive Rumors

New research raises the possibility that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis. By studying triple-negative... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.